Oncogene-induced senescence: An essential role for Runx

Cell Cycle

Volumn 7, Issue 15, 2008, Pages 2333-2340

  Kilbey, Anna ^a,b   Terry, Anne ^a   Cameron, Ewan R ^a   Neil, James C ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cyclins; Functional pathways; Runx; Senescence; Tumour supressor

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR RUNX;

CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DAMAGE; GENE; GENE FUNCTION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE INDUCED SENESCENCE; ONCOGENE RAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; RUNX GENE; SENESCENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 48849117698     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6368     Document Type: Review

References (108)

1. INK4a. Cell 1997; 88:593-602.
2. Patil CK, Mian IS, Campisi J. The thorny path linking cellular senescence to organismal aging. Mech Ageing Dev 2005; 126:1040-5.
3. Lin AW, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12:3008-19.
4. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12:2997-3007.
5. Ferbeyre G, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002; 22:3497-508.
6. Deng Q, Liao R, Wu BL, Sun P. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004; 279:1050-9.
7. Braig M, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436:660-5.
8. Collado M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.
9. Michaloglou C, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4.
10. Dankort D, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007; 21:379-84.
11. Sarkisian CJ, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007; 9:493-505.
12. Blagosklonny MV. Cell senescence: hypertrophic arrest beyond the restriction point. J Cell Physiol 2006; 209:592-7.
13. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. Chromosoma 2007; 116:431-40.
14. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007; 27:2343-58.
15. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008.
16. ARF links the tumour suppressor p53 to Ras. Nature 1998; 395:125-6.
17. Wang W, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22:3389-403.
18. Floyd HS, et al. Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis 2005; 26:2196-206.
19. Sun P, et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007; 128:295-308.
20. Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003; 8:131-44.
21. Kip1. J Biol Chem 2000; 275:21960-8.
22. Brachmann SM, et al. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 2005; 25:2593-606.
23. Courtois-Cox S, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10:459-72.
24. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature 2005; 436:725-30.
25. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
26. Tanaka T, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 2006; 5:1940-5.
27. Hemann MT, Narita M. Oncogenes and senescence: breaking down in the fast lane. Genes Dev 2007; 21:1-5.
28. Di Micco R, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42.
29. Kilbey A, et al. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 2007; 67:11263-71.
30. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004; 432:640-5.
31. ARF. Cell 1997; 91:649-59.
32. Ventura A, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-5.
33. Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60.
34. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7:1074-82.
35. Inoue K, et al. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 2000; 14:1797-809.
36. Bernardi R, et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004; 6:665-72.
37. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005; 25:220-32.
38. Pearson M, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406:207-10.
39. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23:5540-55.
40. Ferbeyre G, et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14:2015-27.
41. Bischof O, et al. Deconstructing PML-induced premature senescence. EMBO J 2002; 21:3358-69.
42. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem 2000; 275:38973-80.
43. MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001; 276:39115-22.
44. Bulavin DV, Kovalsky O, Hollander MC, Fornace AJ Jr. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 2003; 23:3859-71.
45. Moller A, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 2003; 63:4310-4.
46. MAPK-mediated activation of the p16(Ink4a)-p19(Arf ) pathway. Nat Genet 2004; 36:343-50.
47. Armata HL, Garlick DS, Sluss HK. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res 2007; 67:11696-703.
48. Tuveson DA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and wide-spread neoplastic and developmental defects. Cancer Cell 2004; 5:375-87.
49. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 1997; 94:9648-53.
50. Wang Y, Blandino G, Oren M, Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998; 17:1923-30.
51. Yuasa Y, et al. Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 1983; 303:775-9.
52. Mitsudomi T, et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991; 6:1353-62.
53. de Stanchina E, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 2004; 13:523-35.
54. Boiko AD, et al. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 2006; 20:236-52.
55. Qian Y, Zhang J, Yan B, Chen X. DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 2008; 283:2896-905.
56. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7:819-22.
57. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8:877-84.
58. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999; 18:4974-82.
59. Jackson JG, Pereira-Smith OM. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res 2006; 66:8356-60.
60. INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8:1291-7.
61. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424:223-8.
62. Sage J, et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 2000; 14:3037-50.
63. Peeper DS, Dannenberg JH, Douma S, te RH, Bernards R. Escape from premature senescence is not sufficient for oncogenic transformation by Ras. Nat Cell Biol 2001; 3:198-203.
64. 1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000; 101:79-89.
65. Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 2003; 23:7719-31.
66. Rowland BD, et al. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2002; 2:55-65.
67. Narita M, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113:703-16.
68. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413:83-6.
69. Arf predisposes mice to tumorigenesis. Nature 2001; 413:86-91.
70. Sebastian T, Malik R, Thomas S, Sage J, Johnson PF. C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J 2005; 24:3301-12.
71. Dannenberg JH, van Rossum A, Schuijff L, te RH. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 2000; 14:3051-64.
72. Masselink H, Vastenhouw N, Bernards R. B-myb rescues ras-induced premature senescence, which requires its transactivation domain. Cancer Lett 2001; 171:87-101.
73. Peeper DS, et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 2002; 4:148-53.
74. Coisy M, et al. Cyclin A repression in quiescent cells is associated with chromatin remodeling of its promoter and requires Brahma/SNF2alpha. Mol Cell 2004; 15:43-56.
75. 2/M promoters. Mol Cell Biol 2005; 25:3737-51.
76. Park JH, et al. Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction. EMBO J 2006; 25:3986-97.
77. Roberts CW, Orkin SH. The SWI/SNF complex - chromatin and cancer. Nat Rev Cancer 2004; 4:133-42.
78. Napolitano MA, et al. Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci 2007; 120:2904-11.
79. Muchardt C, Bourachot B, Reyes JC, Yaniv M. ras transformation is associated with decreased expression of the brm/SNF2alpha ATPase from the mammalian SWI-SNF complex. EMBO J 1998; 17:223-31.
80. Campisi J, d'Adda dF. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40.
81. Ye X, et al. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007; 27:2452-65.
82. Beausejour CM, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22:4212-22.
83. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003; 278:11731-4.
84. Chua KF, et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2005; 2:67-76.
85. Abad M, et al. Ing1 mediates p53 accumulation and chromatin modification in response to oncogenic stress. J Biol Chem 2007; 282:31060-7.
86. Wotton SF, et al. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 2004; 23:5476-86.
87. Blyth K, et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006; 66:2195-201.
88. kip1. Nature 2000; 404:782-87.
89. 1-phase cell cycle regulation. Nat Rev Mol Cell Biol 2004; 5:355-66.
90. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14:159-69.
91. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997; 16:5334-44.
92. Iovino F, Lentini L, Amato A, Di Leonardo A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer 2006; 5:38.
93. Villagra A, et al. Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity. J Biol Chem 2006; 281:22695-706.
94. Zaidi SK, et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 2007; 104:19861-6.
95. Kadam S, Emerson BM. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 2003; 11:377-89.
96. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell cycle control. EMBO J 2007; 26:752-63.
97. Cho HJ, et al. Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem 2002; 277:19358-66.
98. Linggi B, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8:743-50.
99. Aikawa Y, et al. Roles of HIPK1 and HIPK2 in. EMBO J 2006; 25:3955-65.
100. Li XL, et al. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair. Oncogene 2007; 26:7231-9.
101. Reed-Inderbitzin E, et al. RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene 2006; 25:5777-86.
102. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem 2006; 98:54-64.
103. Motoda L, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells 2007; 25:2976-86.
104. Niimi H, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006; 20:635-44.
105. Roumier C, et al. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Leukemia 2006; 20:433-6.
106. Ito K, et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005; 65:7743-50.
107. Lau QC, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006; 66:6512-20.
108. Subramaniam MM, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2008.